Trials / Terminated
TerminatedNCT00566241
IGF-1 Therapy in Patients With Cystic Fibrosis
An Investigation Into the Use of IGF-1 Therapy in Patients With Cystic Fibrosis
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Stony Brook University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
28 week pilot study to examine the efficacy of recombinant human IGF-1 on body weight and composition in adults with cystic fibrosis.
Detailed description
28 week, double blind, cross over study to determine the efficacy of rhIGF-1 on body weight and body composition in patients with cystic fibrosis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | recombinant human IGF-1 | rhIGF-1 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2008-06-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2007-12-03
- Last updated
- 2013-01-28
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00566241. Inclusion in this directory is not an endorsement.